Saturday 17 October 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.
3.73
0.23
−5.81%
Follow BIAF
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 4 | 2 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (0.44) | (7.95) | (13.01) | (10.54) |
P/S ratio |
— | — | — | 0.00 | 5.83 | 1.18 | 0.33 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | 3.99 | (21.31) | (35.80) | (22.01) |
Beneish M-Score |
— | — | — | — | 843.49 | (2.03) | (5.49) |
P/Operating CF |
— | — | — | (5.40) | (9.13) | (6.59) | (0.79) |
P/B ratio |
— | — | — | 0.64 | 3.04 | 4.25 | 0.28 |
Price to Tangible BV |
— | — | — | 0.64 | 5.64 | 26.18 | 0.39 |
EV/Sales |
— | — | — | 0.00 | 5.22 | 1.13 | (0.61) |
EV/EBITDA |
— | — | — | 2.13 | 0.00 | 0.00 | 0.37 |
EV/Operating CF |
— | — | — | 1.02 | (2.19) | (1.46) | 0.40 |
EV/FCF |
— | — | — | 1.02 | (2.18) | (1.44) | 0.40 |
Quick Ratio |
0.12 | 0.01 | 0.10 | 10.03 | 1.62 | 0.72 | 2.41 |
Current Ratio |
0.13 | 0.01 | 0.11 | 10.50 | 1.77 | 0.87 | 2.60 |
Net Debt/EBITDA |
(1.12) | (3.84) | (5.81) | 5.74 | 0.26 | 0.06 | 0.57 |
Debt/Assets |
608.83% | 6,872.73% | 781.97% | 2.07% | 10.16% | 9.77% | 6.20% |
Debt/Equity |
(0.99) | (0.91) | (0.72) | 0.02 | 0.17 | 0.24 | 0.09 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.25 | 1.27 | 0.71 |
Operating CF/Net income |
0.75 | 0.30 | 0.32 | 0.50 | 0.76 | 0.80 | 0.63 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.11) | (0.09) | (0.13) | (0.12) |
Interest Coverage |
(28.42) | (13.59) | (2.20) | (1.58) | (214.91) | (96.79) | (238.12) |
| 0.00% | 62.79% | 41.00% | 343.53% | (99.84%) | (242.44%) | (301.83%) | |
| 0.00% | (1,807.24%) | (791.34%) | (119.60%) | (77.80%) | (122.70%) | (170.65%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (173.68%) | (262.35%) | (438.42%) |
Return on Tangible Assets |
81.70% | 66.12% | 54.55% | (73.88%) | (363.50%) | 26,278.49% | (302.76%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 798.44 | 116.99 | 44.41 | 32.10 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 31,754.17% | 68.10% | 19.04% | 33.90% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 51,687.50% | 268.14% | 106.21% | 160.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.33 | 0.19 |
Share Based Compensation of Revenue |
— | — | 0.00% | 5,179.17% | 29.57% | 10.57% | 10.90% |
Graham Net Nets |
— | — | — | 1.54 | 0.04 | (0.11) | 1.91 |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (111.74%) | (53.28%) | (84.66%) | (1,334.92%) |
Free Cash Flow Yield |
— | — | — | (57.99%) | (41.08%) | (66.42%) | (462.09%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.48 | 130.54 | 346.74 | 53.68 |
Operating CF per Share |
(0.34) | (0.30) | (347.29) | (407.08) | (311.23) | (269.07) | (81.26) |
Capex per Share |
0.00 | 0.00 | 0.00 | (22.00) | (1.18) | (2.93) | (0.53) |
Free Cash Flow per Share |
(0.34) | (0.30) | (347.29) | (429.08) | (312.41) | (272.00) | (81.79) |
Cash per Share |
0.08 | 0.01 | 230.61 | 1,141.38 | 145.44 | 40.94 | 56.18 |
Shareholders Equity per Share |
(0.55) | (1.49) | (2,676.39) | 1,104.34 | 250.27 | 96.37 | 63.39 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.55) | (1.49) | (2,676.39) | 1,104.34 | 250.27 | 96.37 | 63.39 |
Free Cash Flow |
(2.49) | (2.21) | (2.05) | (4.29) | (6.06) | (7.34) | (9.39) |
Working Capital |
(4.08) | (11.00) | (11.60) | 10.82 | 1.72 | (0.41) | 4.66 |
Capital Expenditures |
(0.01) | 0.00 | — | (0.22) | (0.02) | (0.08) | (0.06) |
Net Current Asset Value |
(4.08) | (11.06) | (15.81) | 10.82 | 0.61 | (1.22) | 3.88 |
EV/EBIT |
— | — | — | 1.03 | 0.00 | 0.00 | 0.35 |
Capex to Sales |
— | — | — | 45.83 | 0.01 | 0.01 | 0.01 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
1.42 | 2.34 | 105.52 | 9.64 | 0.54 | 1.61 | 1.90 |
Cash ROIC |
(449.49%) | 235.18% | 66.84% | (18.89%) | (71.20%) | (169.07%) | (65.17%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.80 | 6.16 | 9.60 | 7.33 |
Accounts Payable Turnover |
0.00 | 0.15 | 0.02 | 0.00 | 3.67 | 7.52 | 4.83 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 145.08 | 259.59 | 104.24 |
Average Days of Payables |
936.50 | 3,146.89 | 17,520.00 | 251,850.00 | 126.80 | 60.23 | 65.79 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 4,015.00 | 3.88 | 1.68 | 4.62 |
Average Receivables |
— | 0.00 | 0.00 | 0.01 | 0.41 | 0.98 | 0.84 |
Average Payables |
— | 0.15 | 0.21 | 0.29 | 0.47 | 0.80 | 0.87 |
Average Inventory |
— | — | — | — | 0.01 | 0.02 | 0.04 |
Average Assets |
— | 0.40 | 0.80 | 6.82 | 10.20 | 7.37 | 8.74 |
Average Common Equity |
— | (11.58) | (15.43) | (2.37) | 7.95 | 3.73 | 4.94 |
Columns are period end dates · fundamentals updated 2 Oct 2026